Glenda Gray to gag Gene Products, Human Immunodeficiency Virus
This is a "connection" page, showing publications Glenda Gray has written about gag Gene Products, Human Immunodeficiency Virus.
Connection Strength
1,293
-
Predictors of HVTN 503 MRK-AD5 HIV-1 gag/pol/nef vaccine induced immune responses. PLoS One. 2014; 9(8):e103446.
Score: 0,468
-
Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study. Lancet Infect Dis. 2014 May; 14(5):388-96.
Score: 0,453
-
Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine. Curr Opin HIV AIDS. 2010 Sep; 5(5):357-61.
Score: 0,356
-
Novel and promiscuous CTL epitopes in conserved regions of Gag targeted by individuals with early subtype C HIV type 1 infection from southern Africa. J Immunol. 2004 Oct 01; 173(7):4607-17.
Score: 0,015